JP2017500562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500562A5 JP2017500562A5 JP2016538603A JP2016538603A JP2017500562A5 JP 2017500562 A5 JP2017500562 A5 JP 2017500562A5 JP 2016538603 A JP2016538603 A JP 2016538603A JP 2016538603 A JP2016538603 A JP 2016538603A JP 2017500562 A5 JP2017500562 A5 JP 2017500562A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- sample
- subject
- kit
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322094.2 | 2013-12-13 | ||
| GBGB1322094.2A GB201322094D0 (en) | 2013-12-13 | 2013-12-13 | Methods and compositions relating to alzheimers disease |
| PCT/GB2014/053692 WO2015087087A1 (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500562A JP2017500562A (ja) | 2017-01-05 |
| JP2017500562A5 true JP2017500562A5 (cg-RX-API-DMAC7.html) | 2018-01-25 |
| JP6803230B2 JP6803230B2 (ja) | 2020-12-23 |
Family
ID=50030903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538603A Active JP6803230B2 (ja) | 2013-12-13 | 2014-12-12 | アルツハイマー病に関するバイオマーカー及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12345717B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3080609B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6803230B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2933398C (cg-RX-API-DMAC7.html) |
| GB (1) | GB201322094D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015087087A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) * | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| EP3242134A1 (en) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of a neurological disease |
| JPWO2018030252A1 (ja) * | 2016-08-09 | 2019-06-20 | 大塚製薬株式会社 | 尿バイオマーカーを用いたアルツハイマー病の診断補助方法 |
| CN110603550A (zh) * | 2016-12-13 | 2019-12-20 | 阿克利互动实验室公司 | 利用导航任务识别生物标志物和利用导航任务进行治疗的平台 |
| WO2019012671A1 (ja) * | 2017-07-13 | 2019-01-17 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
| JP7696721B2 (ja) | 2017-10-31 | 2025-06-23 | ジーイー・ヘルスケア・リミテッド | 認知症の病理学および／または転帰を診断するための医療システム |
| GB201814807D0 (en) * | 2018-09-12 | 2018-10-24 | Univ Newcastle | Dementia Biomarkers |
| US20220120765A1 (en) * | 2019-01-09 | 2022-04-21 | Washington University | Multiplexed assay and methods of use thereof |
| US11860170B2 (en) * | 2019-05-16 | 2024-01-02 | Procisedx Inc. | Assay method for the detection of VCAM-1 and alpha-2-macroglobulin in blood |
| US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
| KR20220104706A (ko) * | 2019-10-28 | 2022-07-26 | 에전 | 알츠하이머병의 침묵 단계를 진단하기 위한 바이오마커 및 이의 용도 |
| WO2021210897A1 (ko) * | 2020-04-14 | 2021-10-21 | 주식회사 지뉴브 | 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물 |
| EP4269556A4 (en) * | 2020-12-28 | 2024-11-13 | MCBI, Inc. | METHOD FOR GENERATING ASSESSMENT SUPPORT INFORMATION, SYSTEM FOR GENERATING ASSESSMENT SUPPORT INFORMATION AND INFORMATION PROCESSING DEVICE |
| WO2022192019A1 (en) * | 2021-03-08 | 2022-09-15 | The Children's Medical Center Corporation | Methods for diagnosis and treatment of alzheimer's disease |
| CN115612728A (zh) * | 2021-07-16 | 2023-01-17 | 深圳先进技术研究院 | 一种神经退行性疾病标志物及其应用 |
| CN114705866A (zh) * | 2022-03-14 | 2022-07-05 | 上海市精神卫生中心（上海市心理咨询培训中心） | 基于血液的遗忘型轻度认知损害早期诊断外周血蛋白标志物、应用及其医疗辅助诊断系统 |
| CN118475840A (zh) * | 2022-06-28 | 2024-08-09 | 株式会社Mcbi | 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置 |
| JPWO2024195825A1 (cg-RX-API-DMAC7.html) * | 2023-03-22 | 2024-09-26 | ||
| CN116790745A (zh) * | 2023-07-03 | 2023-09-22 | 复旦大学 | 阿尔茨海默病临床前期疾病转化的标志物及其筛选方法 |
| WO2025057945A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人三重大学 | 対象が脳アミロイド血管症を有するかを判定するための方法、アルツハイマー病に対する抗アミロイドβ抗体による治療の副作用のリスクまたは存在を判定するための方法、およびアルツハイマー病に対する抗アミロイドβ抗体による治療の対象を選択するための方法、ならびにそのための組成物およびキット |
| CN117538545B (zh) * | 2024-01-09 | 2024-07-05 | 上海众启生物科技有限公司 | 一种用于阿尔茨海默症检测的蛋白抗原组合及应用 |
| WO2025168038A1 (en) * | 2024-02-07 | 2025-08-14 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for ameliorating impairment of regenerative and cognitive function |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| WO2003046566A2 (en) * | 2001-11-23 | 2003-06-05 | Syn.X Pharma, Inc. | Pedf biopolymer markers predictive of alzheimers disease |
| DK1535076T3 (da) | 2002-08-23 | 2008-11-24 | Bayer Healthcare Ag | Polypeptid-biomarkörer til diagnose af Alzheimers sygdom |
| EP1692520A2 (en) * | 2003-11-19 | 2006-08-23 | Satoris, Inc. | Method for diagnosis, stratification and monitoring of alzheimer's disease |
| GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| DE102010026238B4 (de) * | 2010-06-29 | 2012-08-16 | Schuberth Gmbh | Schutzhelm und Tragkorb für einen Schutzhelm |
-
2013
- 2013-12-13 GB GBGB1322094.2A patent/GB201322094D0/en not_active Ceased
-
2014
- 2014-12-12 WO PCT/GB2014/053692 patent/WO2015087087A1/en not_active Ceased
- 2014-12-12 JP JP2016538603A patent/JP6803230B2/ja active Active
- 2014-12-12 CA CA2933398A patent/CA2933398C/en active Active
- 2014-12-12 US US15/104,149 patent/US12345717B2/en active Active
- 2014-12-12 EP EP14830849.7A patent/EP3080609B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500562A5 (cg-RX-API-DMAC7.html) | ||
| Jacobs et al. | Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau | |
| Zhang et al. | Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease | |
| Hesse et al. | Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke | |
| Roche et al. | Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers | |
| Ottervald et al. | Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers | |
| Romeo et al. | CSF proteome: a protein repository for potential biomarker identification | |
| Shen et al. | Proteomics analysis of blood serums from Alzheimer’s disease patients using iTRAQ labeling technology | |
| JP2016533499A5 (cg-RX-API-DMAC7.html) | ||
| Daniele et al. | α-Synuclein heterocomplexes with β-amyloid are increased in red blood cells of Parkinson’s disease patients and correlate with disease severity | |
| AU2014311258B2 (en) | Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases | |
| US6670137B2 (en) | Differential diagnosis of neurological diseases | |
| Bednarska-Makaruk et al. | Homocysteine metabolism and the associations of global DNA methylation with selected gene polymorphisms and nutritional factors in patients with dementia | |
| Sjögren et al. | Advances in the detection of Alzheimer's disease—use of cerebrospinal fluid biomarkers | |
| Lee et al. | Plasma levels of neuron-and astrocyte-derived exosomal amyloid beta1-42, amyloid beta1-40, and phosphorylated tau levels in schizophrenia patients and non-psychiatric comparison subjects: relationships with cognitive functioning and psychopathology | |
| Datta et al. | Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia | |
| Yoo et al. | Longitudinal profiling of oligomeric Aβ in human nasal discharge reflecting cognitive decline in probable Alzheimer’s disease | |
| Cutler et al. | Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium‐derived factor: two novel biomarkers of Alzheimer's disease in human plasma | |
| Maetzler et al. | Comparable autoantibody serum levels against amyloid-and inflammation-associated proteins in Parkinson’s disease patients and controls | |
| Akuffo et al. | The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone | |
| Veitinger et al. | A platelet protein biochip rapidly detects an Alzheimer’s disease-specific phenotype | |
| Nakajima et al. | Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus | |
| US20110143380A1 (en) | Alzheimer's disease biomarkers and methods of use | |
| JP2018516849A5 (cg-RX-API-DMAC7.html) | ||
| Davidsson et al. | Proteome studies of CSF in AD patients |